Lisdexamfetamine is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients ages 6 years and above. Lisdexamfetamine is indicated for the treatment of Moderate to Severe Binge Eating Disorder (BED) for patients over 18 years.
Limitation of Use: Lisdexamfetamine is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Lisdexamfetamine for the treatment of obesity have not been established.
Out-licensing: offered for all international market
* Product availability is subject to patent restrictions in countries where applicable patents are in effect
